{"id":"conventional-abvd","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"30-50%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of these drugs works synergistically to induce apoptosis in cancer cells, with Adriamycin and Dacarbazine causing DNA damage, Bleomycin inducing DNA strand breaks, and Vinblastine inhibiting microtubule formation.","oneSentence":"This chemotherapy regimen combines Adriamycin, Bleomycin, Vinblastine, and Dacarbazine to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:28:33.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"Non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT01712490","phase":"PHASE3","title":"A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-11-09","conditions":"Hodgkin Lymphoma","enrollment":1334},{"nctId":"NCT03407144","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-09","conditions":"Hodgkin Lymphoma","enrollment":340},{"nctId":"NCT03033914","phase":"PHASE1, PHASE2","title":"A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01-25","conditions":"Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT07171827","phase":"NA","title":"Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Helwan University","startDate":"2023-03-01","conditions":"Anti-CD30, Brentuximab, Doxorubicin","enrollment":60},{"nctId":"NCT03159897","phase":"PHASE3","title":"FIL Study on ABVD DD-DI as Upfront Therapy in HL.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2017-08-01","conditions":"Hodgkin Lymphoma","enrollment":500},{"nctId":"NCT03615664","phase":"PHASE2","title":"The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD","status":"COMPLETED","sponsor":"Polish Lymphoma Research Group","startDate":"2017-11-06","conditions":"Hodgkin's Lymphoma","enrollment":115},{"nctId":"NCT05066555","phase":"","title":"Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2020-04-08","conditions":"Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT03712202","phase":"PHASE2","title":"Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-11-28","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma","enrollment":155},{"nctId":"NCT04638790","phase":"PHASE3","title":"First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)","status":"RECRUITING","sponsor":"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","startDate":"2020-02-01","conditions":"Hodgkin Lymphoma, Adult","enrollment":300},{"nctId":"NCT06104878","phase":"","title":"A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2023-12-31","conditions":"Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT01390584","phase":"PHASE2","title":"Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-05-24","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT05490953","phase":"PHASE4","title":"Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"University of Guadalajara","startDate":"2022-07-11","conditions":"Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT01118026","phase":"PHASE2","title":"Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-09","conditions":"Lymphoma","enrollment":101},{"nctId":"NCT00654732","phase":"PHASE2","title":"Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-03-19","conditions":"Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8","enrollment":58},{"nctId":"NCT03527628","phase":"PHASE2","title":"OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy","status":"UNKNOWN","sponsor":"King Abdullah International Medical Research Center","startDate":"2018-01-01","conditions":"Classical Hodgkin Lymphoma, Hodgkin Lymphoma (Category), Hodgkin Disease","enrollment":220},{"nctId":"NCT00369681","phase":"PHASE2","title":"Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-05","conditions":"Lymphoma","enrollment":51},{"nctId":"NCT00722865","phase":"PHASE2","title":"Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT00795613","phase":"PHASE2","title":"Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)","status":"UNKNOWN","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2008-06","conditions":"HODGKIN LYMPHOMA","enrollment":450},{"nctId":"NCT00005090","phase":"PHASE3","title":"S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2000-04","conditions":"Lymphoma","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":69,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BLEOMICINE TEVA","DOXORUBICINE TEVA","VELBE","NATULAN"],"phase":"phase_2","status":"active","brandName":"CONVENTIONAL ABVD","genericName":"CONVENTIONAL ABVD","companyName":"Ospedale Santa Croce-Carle Cuneo","companyId":"ospedale-santa-croce-carle-cuneo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This chemotherapy regimen combines Adriamycin, Bleomycin, Vinblastine, and Dacarbazine to target rapidly dividing cancer cells. Used for Hodgkin lymphoma, Non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}